Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan.
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2425535. doi: 10.1080/21645515.2024.2425535. Epub 2024 Nov 18.
Compared with Europe and America, adoption of human papillomavirus (HPV) vaccination into national immunization programs across the Asia-Pacific (AP) region has remained low. Moreover, HPV burden in this region has not been reviewed comprehensively. Therefore, this systematic literature review (SLR) aimed to summarize the clinical and economic burden of HPV and HPV-related diseases in select AP areas. An SLR was conducted January 2000-February 2022 using MEDLINE/Embase. Observational studies reporting incidence, prevalence, costs, or healthcare resource utilization (HCRU) of HPV and HPV-related disease among adults (≥18 years) from select AP areas were included. A total of 254 publications were included. Reported incidence per 100,000 person-years was 15.4-252.0 for cervical cancer ( = 5 publications), 0.2-55.5 for head and neck cancer ( = 7 publications), and 0.2-13.7 for anal cancer ( = 4 publications). Prevalence rates were 9.1%-100% for cervical cancer ( = 40 publications), 0.0%-95.6% for head and neck cancer ( = 48 publications), 0.0%-100% for anal cancer ( = 4 publications), 36.0%-79.6% for penile cancer ( = 4 publications), and 44.0%-82.0% for vaginal/vulvar cancer ( = 3 publications). Few studies reported on costs or HCRU, and high data variability was observed. Despite data variability, the high burden of HPV and HPV-related diseases makes clear the need for effective HPV screening, greater education, and reductions in vaccine hesitancy, particularly among lower- and middle-income areas. Improved data collection measures should be considered in data-scarce areas to better inform policy decision-making and improve monitoring of the impact of HPV vaccination.
与欧美相比，亚太地区（AP）将人乳头瘤病毒（HPV）疫苗纳入国家免疫计划的比例仍然较低。此外，该地区 HPV 的负担尚未得到全面审查。因此，本系统文献综述（SLR）旨在总结亚太地区部分地区 HPV 和 HPV 相关疾病的临床和经济负担。本 SLR 于 2000 年 1 月至 2022 年 2 月使用 MEDLINE/Embase 进行。纳入了来自亚太地区部分地区的报告成年人（≥18 岁）中 HPV 和 HPV 相关疾病发病率、患病率、成本或医疗资源利用（HCRU）的观察性研究。共纳入 254 篇出版物。宫颈癌（=5 篇出版物）每 100,000 人年的报告发病率为 15.4-252.0，头颈部癌症（=7 篇出版物）为 0.2-55.5，肛门癌（=4 篇出版物）为 0.2-13.7。宫颈癌（=40 篇出版物）的患病率为 9.1%-100%，头颈部癌症（=48 篇出版物）为 0.0%-95.6%，肛门癌（=4 篇出版物）为 0.0%-100%，阴茎癌（=4 篇出版物）为 36.0%-79.6%，阴道/外阴癌（=3 篇出版物）为 44.0%-82.0%。很少有研究报告成本或 HCRU，并且观察到数据变异性很大。尽管数据存在变异性，但 HPV 和 HPV 相关疾病的高负担清楚地表明需要进行有效的 HPV 筛查、加强教育以及减少疫苗犹豫，尤其是在中低收入地区。应在数据匮乏地区考虑改进数据收集措施，以更好地为政策决策提供信息，并监测 HPV 疫苗接种的影响。
